Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 ...

During clinical trials, Bristol Myers Squibb's KarXT was said to offer better treatment with fewer side effects. Meanwhile, Pfizer's sickle cell disease treatment Oxbryta was withdrawn from all ...

A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...